Acquisition of TAS6417 and Drug Discovery Portfolio through Cullinan Pearl Acquisition

An individual M&A transaction involving the acquisition of Cullinan Pearl Corp., an equity-method affiliate, as a wholly owned subsidiary and the acquisition of drug discovery assets, including TAS6417. The theme is the expansion of Taiho Pharmaceutical's drug discovery portfolio through the acquisition.